Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology, AstraZeneca Renew Target Discovery Collaboration

Published: Thursday, July 03, 2014
Last Updated: Thursday, July 03, 2014
Bookmark and Share
Initiative brings together global expertise to share compound libraries and streamline drug discovery.

MRC Technology and AstraZeneca announced the renewal of their strategic collaboration which focuses on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics for the treatment of serious disease in the areas of oncology, inflammation and diabetes. The strategic collaboration enables MRC Technology scientists to access compounds from the AstraZeneca compound library, for screening against nominated drug targets at MRC Technology. The renewal builds on the success of the alliance to date, with multiple projects being initiated with the aim of leading to development of innovative medicines.

Under the terms of the agreement, the companies will combine selected compounds from AstraZeneca’s compound collection with MRC Technology’s compound collection, resulting in a library of over 200,000 compounds available for screening against novel targets. MRC Technology will be responsible for screening the libraries, hit validation and optimization of selected compounds, as agreed by a joint steering committee. The initiative provides an ideal opportunity to combine the strengths in drug discovery and development of AstraZeneca with the rich knowledge of targets and disease biology available in academia provided by MRC Technology’s Centre for Therapeutics Discovery.

Justin Bryans, MRC Technology’s Director of Drug Discovery, said: “The collaboration with AstraZeneca this far has been very promising. By continuing to work together we will generate more opportunities to translate early stage academic research into potential new therapies.”

Peter Simpson, Director of Screening Sciences, AstraZeneca, said: “Supporting innovative science with leading external partners is at the heart of AstraZeneca’s Open Innovation Strategy. We look forward to continuing our strong collaboration with MRCT with a view to further building our portfolio of early target ideas and external drug discovery capabilities.  Dr Simpson added “This collaboration complements our recently announced strategic alliance with the Medical Research Council to create the AstraZeneca MRC centre for Lead Discovery within the new AstraZeneca research campus in Cambridge in 2016.”

Both parties retain ownership of their respective compounds. Individual projects chosen to go forward will trigger option fees with further research and license agreements negotiated at that time. Further financial terms of the agreement have not been disclosed.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology Appoints Technology Transfer Director
Appointment of Andrew Farquharson as Director from 1 September.
Wednesday, July 08, 2015
MRC Technology, Peptinnovate Collaborate
This partnership has been formed to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
Wednesday, June 10, 2015
MRC Technology and NYU School of Medicine Collaborate
Collaboration will develop develop biologics for inflammatory bone disease.
Thursday, April 23, 2015
MRC Technology Appoints Finance Director
MRC Technology, an independent life science medical research charity, has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim Finance Director in August 2014.
Friday, April 17, 2015
MRC Technology Negotiates Licence Deal with Quantifoil Micro Tools GmbH for Ultrastable Gold Support (UltrAuFoil) Technology
The gold supports enable the determination of currently intractable protein structures by electron cryomicroscopy.
Tuesday, March 31, 2015
First Treatment Approved Under EAMS
New immunotherapy (pembrolizumab) made available in the UK for treatment of adults with advanced melanoma.
Friday, March 13, 2015
First Treatment Approved under EAMS Developed Using Antibody Humanization Expertise at UK’s MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma.
Wednesday, March 11, 2015
MRC Technology Launches Respiratory ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease.
Monday, March 02, 2015
MRC Technology Appoints General Counsel and Company Secretary
Dr Edward Bliss will join MRCT on 16 March.
Wednesday, February 04, 2015
MRC Technology and Yabao Pharmaceuticals Announce Exclusive Partnership
Partnership in China to develop novel therapeutics for Parkinson’s disease.
Friday, November 28, 2014
Charities Pledge to Inject Millions to Jump Start Drug Development for Brain Diseases
MRC Technology to lead Neurodegeneration Medicines Acceleration Programme to uncover promising drugs in pharma libraries.
Tuesday, November 18, 2014
MRC Technology and Proximagen Collaborate
Project will investigate a small molecule solution for Macrophage migration inhibitory factor.
Monday, October 13, 2014
Dr. John Stageman Appointed Chair of the Board for MRC Technology
Dr. Stageman has a wealth of experience in the pharmaceutical industry and biotechnology research.
Wednesday, October 01, 2014
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Friday, September 05, 2014
MRC Technology Negotiates License with Bio-Techne for MRC’s GOPAL Protein Synthesis Technology
Technology enables production of ubiquitin reagents and other proteins for use in drug discovery.
Wednesday, August 27, 2014
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!